Ab­b­Vie preps for an on­slaught of Hu­mi­ra biosim­i­lars in 2023, with Skyrizi and Rin­voq to fill the gap for now

Un­veiled Fri­day morn­ing, Ab­b­Vie’s Q3 re­sults and earn­ings call show a com­pa­ny brac­ing for what could be steep Hu­mi­ra loss­es with the com­ing of biosim­i­lar com­peti­tors ear­ly next year, even as the rest of its im­munol­o­gy fran­chise out­paces ini­tial ex­pec­ta­tions.

Be­gin­ning in Jan­u­ary, Ab­b­Vie’s and the world’s best-sell­ing drug Hu­mi­ra (adal­i­mum­ab) will fi­nal­ly see biosim­i­lar com­pe­ti­tion in the US, with the en­trance of Am­gen’s biosim­i­lar, fol­lowed by Sam­sung, Boehringer, Vi­a­tris, and San­doz launch­ing their ver­sions of adal­i­mum­ab next June and Ju­ly.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN